News | May 13, 2009

ACR Image Metrix to Provide Infrastructure for PET/CT Bone Imaging Study

May 13, 2009 - American College of Radiology (ACR) Image Metrix has been chosen by the Academy of Molecular Imaging (AMI) to provide data and image storage infrastructure for a new study to compare the effectiveness of conventional planar 99mTc-MDP bone imaging with 18F-sodium fluoride PET/CT (18F-NaF) at detecting bony metastases in patients with breast, prostate and non–small-cell lung cancers.

The protocol was developed in conjunction with the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) and calls for data collection on more than 500 patients at 13 sites nationwide.

“Just as early detection of cancer is important, early detection of any spread of a cancer is vitally important to determining the best and most timely treatment for patients. PET and PET/CT are serving an increasingly important role in this care. Each refinement in care can make a big difference in the success of treatment for additional patients. ACR Image Metrix is proud to serve such a significant role in this important trial as the selected CRO [Contract Research Organization],” said ACR Image Metrix Chief Scientific Officer Bruce J. Hillman, M.D., FACR, who worked with AMI investigators to develop the protocol for the research.

Cancer patients undergo more than 2 million planar 99mTc-MDP scans each year to determine whether cancer has spread from the organ of primary diagnosis to their bones. However, the test may miss some disease. 18F-NaF PET/CT bone scanning may have advantages over the conventional method in that it is often able to find smaller metastases and differentiate more accurately between cancerous and non-cancerous conditions.

“ACR Image Metrix is unique in the CRO landscape regarding its ability to assist in protocol development then transmit, archive, and retrieve imaging data for such important trials. We are proud of our ability to substantively contribute to advances in patient care by providing significant infrastructure for cutting edge medical research,” said Michal Morales, General Manager of ACR Image Metrix.

For more information: www.acr.org and www.ami-imaging.org

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Overlay Init